Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CINRYZE for Acute Antibody-Mediated Rejection in Kidney Transplants
NCT01147302Phase 2Completed
- Sponsor
- Takeda
- Start
- Aug 2011
- Primary completion
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in antibody mediated rejection (AMR) comparing Cinryze with Placebo (2 arms). Primary endpoint: Change From Baseline in Histopathology Endpoints at Day 20. Started Aug 2011; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT01147302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147302.